Lumexa Imaging (NASDAQ:LMRI) Announces Earnings Results

Key Points

• Q4 and full‑year results beat prelim expectations — consolidated Q4 revenue was $267.7M (+7.9% YoY) with adjusted EBITDA $63.8M (23.8% margin), and full‑year revenue was $1.023B with adjusted EBITDA $230.2M.
• IPO proceeds used to cut leverage — the company used about $406M of net IPO proceeds to pay down debt, reducing leverage to ~3.5x, securing S&P B+ and Moody’s B2 ratings and expected annual interest savings of more than $50M.
• Growth, operational improvements and 2026 guidance — Lumexa is targeting 8–10 de novo openings per year (nine in 2025) and expanding AI Fast Scan to boost MRI capacity (~40% increase), while reiterating 2026 guidance of $1.045B–$1.097B revenue and $234M–$242M adjusted EBITDA, with Q1 expected roughly flat YoY due to pull‑forward and storm disruptions.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.71), Zacks reports. The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $262.72 million.

Here are the key takeaways from Lumexa Imaging's conference call:

• Q4 and full‑year results beat preliminary expectations — consolidated Q4 revenue was $267.7M (+7.9% YoY) and adjusted EBITDA was $63.8M (+18.6%) with a 23.8% margin; full‑year revenue was $1.023B and adjusted EBITDA $230.2M.
• Completed an IPO and used approximately $406M of net proceeds to pay down debt, reducing leverage to ~3.5x, securing upgraded ratings (S&P B+, Moody’s B2) and expected annual interest savings of more than $50M.
• Growth strategy remains focused on same‑center expansion and network growth — targeting 8–10 de novo openings per year (record nine opened in 2025), accelerating JV partnerships (e.g., UPMC) and disciplined tuck‑in M&A.
• Operational efficiency and tech adoption are driving throughput — AI‑enabled Fast Scan increased MRI schedule capacity by ~40% (50% fleet adoption end‑2025; ~two‑thirds expected by end‑2026) and a Ferrum Health partnership gives rapid access to FDA‑cleared AI apps.
• 2026 guidance reiterated (revenue $1.045B–$1.097B; adjusted EBITDA $234M–$242M; adjusted EPS $0.71–$0.77), but Q1 is expected roughly flat YoY due to some volume pull‑forward into Q4 and storm disruptions that the company expects to recover over the year.

Lumexa Imaging Stock Performance

NASDAQ LMRI opened at $7.57 on Friday. Lumexa Imaging has a 12-month low of $7.23 and a 12-month high of $19.45. The firm has a 50 day simple moving average of $13.53.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial raised shares of Lumexa Imaging from an "outperform" rating to a "strong-buy" rating and set a $23.00 target price for the company in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Lumexa Imaging presently has a consensus rating of "Strong Buy" and a consensus price target of $23.00.

Institutional Investors Weigh In On Lumexa Imaging

Several large investors have recently made changes to their positions in LMRI. Barclays PLC bought a new stake in Lumexa Imaging in the 4th quarter valued at $133,000. Sandia Investment Management LP acquired a new position in shares of Lumexa Imaging in the fourth quarter valued at $185,000. Hudson Bay Capital Management LP acquired a new position in shares of Lumexa Imaging in the fourth quarter valued at $237,000. Oxford Asset Management LLP bought a new position in shares of Lumexa Imaging in the fourth quarter valued at about $670,000. Finally, Burkehill Global Management LP acquired a new stake in shares of Lumexa Imaging during the 4th quarter worth about $925,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.